Loading...
Loading...
Citigroup reiterated its Buy rating on Medtronic
MDT and increased its price target from $47 to $50.
Citigroup said, "We estimate that MDT would garner a 29% share of STJ's CRM sales on an annual basis is Durata is withdrawn from the market, or $238MM. Assuming minimal incremental expenses, we believe these sales would generate a nearly 70% incremental margin or $0.13 in EPS. We have MDT garnering a lower share benefit than BSX on the assumption that customers would be more inclined to reduce their risk of having too much share controlled by one vendor."
Medtronic closed at $43.27 on Friday.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in